Business Wire

HCL Group and UpLink Launch Fifth Global Aquapreneur Innovation Challenge to Advance Future Water Systems

22.4.2026 13:16:00 CEST | Business Wire | Press Release

Share

HCL Group, in partnership with UpLink - the early-stage innovation initiative of the World Economic Forum - has launched the fifth global challenge under the Aquapreneur Innovation Initiative, titled Transforming Water Systems. Applications will be open from 22 April to 4 June 2026. The top 10 winners will receive a total financial award of CHF 1.75 million. For details on eligibility and application criteria, visit: UpLink - Transforming Water Systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421866128/en/

The Aquapreneur Innovation Initiative is a five-year, CHF 15 million collaboration between UpLink, HCL Group, and the World Economic Forum’s Food and Water Initiative, focused on building a global innovation ecosystem for freshwater solutions.

Important Dates to Note

22 April to 4 June 2026

Open for submissions

July to August 2026

Review and selection process

January 2027

Announcement of the winners

As water systems face increasing pressure from climate variability, industrial demand, and infrastructure constraints, the challenge shifts the focus from isolated issues to systemic risks. It seeks innovations that improve reliability, efficiency, and decision-making across water systems, particularly in strengthening supply reliability, redesigning water-intensive processes, and enhancing system intelligence.

The challenge invites solutions across three key focus areas:

  1. Ensuring Water Supply Reliability – Innovations that ensure dependable water supply at both the site level and across broader water systems, from individual facilities and campuses to citywide and regional networks. This focus area prioritizes solutions that secure availability, continuity and quality of supply under increasing variability, disruption and operational stress, as climate extremes, energy instability and contamination risks increasingly affect interconnected systems.
  2. Redesigning Water-Intensive Industrial and Digital Processes – Innovations that fundamentally re-engineer processes where water use, heat management and production continuity are tightly coupled. This focus area prioritizes solutions that reduce water intensity, improve system stability and decouple performance from freshwater dependence in water-critical operations.
  3. Water System Intelligence for Decision Making - Technologies that improve visibility, prediction and decision-making across water systems, from facility operations to basin-scale planning. This focus area prioritizes tools that turn data into actionable decisions, strengthening preparedness and enabling earlier intervention in response to water stress, quality changes, and climate-driven volatility.

During the launch of the challenge, Sundar Mahalingam, President, Strategy at HCL Group, said, “Water is fast emerging as critical infrastructure, shaping economic resilience, industrial continuity, and technological progress. The future of water is no longer just about supply, but about systems strained by climate volatility, industrial dependence, and decision-making gaps. Through this challenge, we aim to drive innovations that secure reliability, re-engineer water-intensive processes, and enable data-driven choices. These efforts have already saved over 14 billion litres of water, treated 1.8 billion litres, and unlocked more than USD 125 million in follow-on funding.”

“Around 20% of global freshwater withdrawals are driven by energy and production systems, with demand rising due to electrification and cooling needs, creating a growing area of pressure and opportunity,” said John Dutton, Head of UpLink at the World Economic Forum. “Early-stage solutions exist, but many lack the partnerships, funding and real-world deployment support needed to scale. Addressing the future of water will require coordinated action across innovators, industry and the public sector. Through this challenge, we aim to support entrepreneurs advancing industrial transformation, climate resilience and data-driven water management, and connect them with the resources needed to scale their impact.”

Evidence from the initiative highlights the catalytic role of funding and partnerships in accelerating early-stage innovation. Around 70% of ventures report that HCL funding was critical, either enabling projects or significantly accelerating delivery, underscoring its role as a de-risking mechanism. Complemented by access to strategic partners, this support has further accelerated the growth of Aquapreneurs, enabling them to enter new markets, launch new products, and strengthen their commercial pathways. As a result, ventures are advancing product development, expanding customer deployments, and building the teams and capabilities needed for sustained growth.

This impact is reflected in venture experiences. One venture noted that the funding allowed it to accelerate key initiatives across hiring, technology development, and market engagement, advancing its roadmap earlier and at greater scale. Another highlighted that the support created the capacity to expand pilot and project delivery capabilities. A third shared that the funding enabled a pilot that would not have been possible otherwise, allowing the venture to move forward immediately rather than continuing to seek external financing.

Selected participants will gain access to funding, mentorship, global visibility, and a network of industry leaders, policymakers, and investors.

About HCL

Founded in 1976 as one of India’s original IT garage start-ups, HCL Group is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978, well before its global peers. Today, the HCL Group has a presence across varied sectors that include technology, healthcare and talent management solutions and comprises three companies – HCL Infosystems, HCLTech and HCL Healthcare. The conglomerate generates annual revenues of over US $14.7B with 227,000 employees operating across 60 countries. For further information, visit www.hcl.com.

About UpLink

UpLink, the World Economic Forum’s early-stage innovation engine, connects purpose-driven innovators with the partnerships, resources and capital they need to scale solutions for the markets and economies critical to a resilient, sustainable and prosperous world. UpLink envisions a future where profit and purpose go hand in hand — where innovation drives competitiveness, inclusion, and long-term value, where economic growth uplifts people while restoring the planet, and where resilience is the foundation of thriving, future-proof economies. For further information, click here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421866128/en/

Contacts

For more details, please contact:
On behalf of HCL:

Shruti Saxena- shruti-saxena@hcl.com / 9654356487
Alisha Bisherwal- alisha.a@hcl.com /8447821231

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press Release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press Release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 14:00:00 CEST | Press Release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press Release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye